JOINT FILING AGREEMENTJoint Filing Agreement • May 9th, 2022 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock of HilleVax, Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13D.
HILLEVAX, INC. STOCK ISSUANCE AGREEMENTStock Issuance Agreement • May 9th, 2022 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations • Delaware
THIS STOCK ISSUANCE AGREEMENT (“Agreement”) is made as of July 2, 2021 by and between HILLEVAX, INC., a Delaware corporation (the “Company”), and TAKEDA VACCINES, INC. (the “Recipient”) in connection with that certain License Agreement, dated as of July 2, 2021 by and between Recipient and the Company (the “License Agreement”) together with that certain Warrant to Purchase Shares of Common Stock (the “Warrant Shares”), dated as of July 2, 2021 (the “Warrant”) (collectively, the “Transaction Agreements”).
